CTLA4 and neoplasm: In the mouse model of lung adenocarcinoma, refractory to an anti-PD-1 and anti-CTLA-4 mAb combination therapy, the use of oxaliplatin in combination with a low-dose of cyclophosphamide increased the lung CTLs/Treg cell ratio sensitizing the tumor to ICIs [24].